Meetings International
SciTechnol

Robert Christopher Brown, J Pharm Sci Emerg Drugs 2018, Volume: 6
DOI: 10.4172/2380-9477-C4-014

International Conference on
PHARMACEUTICAL CHEMISTRY &
International Conference on
SYNTHETIC BIOLOGY

July 16-17, 2018 | Paris, France

Robert Christopher Brown

Synthetic Genomics Inc., USA

Genomic tools to enable synthetic biology

Today's rapid DNA sequencing technology and annotation pipelines are able to push data to the internet. This can work well for prokaryotic genomes and metagenomes. There exists a huge disparity within Eukaryotic genome annotation with regards to gene models and predictions outside of mammalian or plant genomics. This workshop aims to prioritize the tools required to improve gene predictions, synthetic biology and gene expression in novel eukaryotic hosts.

Biography

Dr. Brown joined Synthetic Genomics in 2007 to build and lead a multifunctional team in the design and development of microbes for the production of advanced biofuels. He now leads SGI's world-class phototrophic strain development group. Dr. Brown has over 20 years of experience in molecular biology and gene expression in the biotechnology sector. Prior to SGI, he was a senior scientist Diversa Corp., developing recombinant expression systems for industrial enzymes and animal vaccines. Earlier in his career, Dr. Brown served in senior research and science roles for Solexa Ltd. (acquired by Illumina), Dow Chemical, Chirotech Ltd. and Chiroscience Plc. Dr. Brown received his Ph.D. in Bacterial Pathogenesis from the Centre of Microbial Research and Microbiology, in the U.K. He has more than 20 issued patents and additional pending applications in various areas of industrial biotechnology

RBrown@SyntheticGenomics.com

Notes: